Nonpeptide cholecystokinin-2 receptor agonists

被引:19
作者
Kalindjian, SB [1 ]
Dunstone, DJ [1 ]
Low, CMR [1 ]
Pether, MJ [1 ]
Roberts, SP [1 ]
Tozer, MJ [1 ]
Watt, GF [1 ]
Shankley, NP [1 ]
机构
[1] James Black Fdn, London SE24 9JE, England
关键词
D O I
10.1021/jm0010668
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
In the course of structural explorations around a series of potent CCK2 receptor antagonists, it was noted that simple N-methylation of the indolic N-H in the parent molecule gave rise to behavior in vivo that was consistent with the compound acting as an agonist. Exploration in vitro confirmed this property, and it was shown that the agonist action could be blocked by the reference CCK2 receptor antagonist, L-365,260. Further examples of this type of modification were explored, and a common theme with regard to agonist behavior was uncovered. Some molecular modeling is also presented in an attempt to throw light on the nature of the ligand receptor interactions that may be giving rise to the differing properties of these, apparently, structurally similar molecules.
引用
收藏
页码:1125 / 1133
页数:9
相关论文
共 31 条
[1]
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity .1. Optimization of the agonist ''Trigger'' [J].
Aquino, CJ ;
Armour, DR ;
Berman, JM ;
Birkemo, LS ;
Carr, RAE ;
Croom, DK ;
Dezube, M ;
Dougherty, RW ;
Ervin, GN ;
Grizzle, MK ;
Head, JE ;
Hirst, GC ;
James, MK ;
Johnson, MF ;
Miller, LJ ;
Queen, KL ;
Rimele, TJ ;
Smith, DN ;
Sugg, EE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (02) :562-569
[2]
The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD 170292 [J].
Bernad, N ;
Burgaud, BGM ;
Horwell, DC ;
Lewthwaite, RA ;
Martinez, J ;
Pritchard, MC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (11) :1245-1248
[3]
OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].
BLACK, JW ;
LEFF, P .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162
[4]
CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides [J].
Bläker, M ;
Ren, Y ;
Seshadri, L ;
McBride, EW ;
Beinborn, M ;
Kopin, AS .
MOLECULAR PHARMACOLOGY, 2000, 58 (02) :399-406
[5]
BENZODIAZEPINE GASTRIN AND BRAIN CHOLECYSTOKININ RECEPTOR LIGANDS - L-365,260 [J].
BOCK, MG ;
DIPARDO, RM ;
EVANS, BE ;
RITTLE, KE ;
WHITTER, WL ;
VEBER, DF ;
ANDERSON, PS ;
FREIDINGER, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (01) :13-16
[6]
Dutta A. S., 1993, SMALL PEPTIDES CHEM
[7]
DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST [J].
GETHER, U ;
JOHANSEN, TE ;
SNIDER, RM ;
LOWE, JA ;
NAKANISHI, S ;
SCHWARTZ, TW .
NATURE, 1993, 362 (6418) :345-348
[8]
[9]
Analysis of variation in L-365,260 competition curves in radioligand binding assays [J].
Harper, EA ;
Roberts, SP ;
Shankley, NP ;
Black, JW .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (07) :1717-1726
[10]
3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents [J].
Henke, BR ;
Willson, TM ;
Sugg, EE ;
Croom, DK ;
Dougherty, RW ;
Queen, KL ;
Birkemo, LS ;
Ervin, GN ;
Grizzle, MK ;
Johnson, MF ;
James, MK .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) :2655-2658